Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
Part of paid clinical trials in Bakersfield, California.
- Sponsor
- California Retina Consultants
- Study ID
- NCT01028248
- Phase
- PHASE1
- Status
- Completed
Conditions
- Central Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab (Lucentis) — DRUG0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
Study Details
The purpose of this study is to determine whether ranibizumab (Lucentis) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
Key Dates
- First listed
- Dec 9, 2009
- Start date
- Jan 31, 2010
- Status verified
- Dec 2013
- Primary completion
- Jun 30, 2012
- Completion
- Jun 30, 2013
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Active Comparator: 2.0 mg Ranibizumab
- Active Comparator: 0.5 mg Ranibizumab
Primary Outcome Measure
The primary outcome measure will be mean change from baseline best-corrected visual acuity, at Months 6 and 12, based on ETDRS visual acuity chart assessment starting distance of 4 meters. [ Time Frame: 6 months and 12 months ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| California Retina Consultants | Bakersfield | California | 93309 | - |
| California Retina Consultants | Santa Barbara | California | 93103 | - |
| California Retina Consultants | Santa Maria | California | 93454 | - |